(Q37590676)

21 August 2017

title

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease (English)

1 reference

21 August 2017

0 references

0 references

Maria Oliva-Hemker

12

0 references

Marian D. Pfefferkorn

series ordinal

7

object named as

Marian D Pfefferkorn

1 reference

21 August 2017

10

Subra Kugathasan

1 reference

21 August 2017

9

Anne M Griffiths

1 reference

21 August 2017

1

Joel R Rosh

1 reference

21 August 2017

6

Joshua D Noe

1 reference

21 August 2017

13

Wallace Crandall

1 reference

21 August 2017

11

David Keljo

1 reference

21 August 2017

3

James Markowitz

1 reference

21 August 2017

16

Jeffrey S Hyams

1 reference

21 August 2017

5

Petar Mamula

1 reference

21 August 2017

2

Trudy Lerer

1 reference

21 August 2017

14

Ryan S Carvalho

1 reference

21 August 2017

Sri R Goli

4

1 reference

21 August 2017

Kathleen T Kelleher

series ordinal

8

1 reference

21 August 2017

David R Mack

series ordinal

15

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

The American Journal of Gastroenterology

21 August 2017

published in

1 reference

21 August 2017

volume

104

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

3042-3049

1 reference

Unravelling the pathogenesis of inflammatory bowel disease

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

A controlled double blind study of azathioprine in the management of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Safety and efficacy of adalimumab in pediatric patients with Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Short-term response to adalimumab in childhood inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Long-term evolution of disease behavior of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Gender differences in presentation and course of disease in pediatric patients with Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.493

21 January 2018

Identifiers

DOI

10.1038/AJG.2009.493

1 reference

21 August 2017

1 reference